Skip to content
OpenHORIZON-HLTH-2027-01-CARE-02HaDEAOne-off

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

A personalised approach to adverse reactions caused by the use of multiple medicines.

Horizon Europe research and innovation action (approximately €8-10 million per project) for personalised approaches that reduce the risk of adverse drug reactions due to polypharmacy, particularly in older people.

Next deadline
91
days
17 February 2027
HORIZON-HLTH-2027-01-CARE-02
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications?

Who
A consortium of at least three independent organisations from three different countries, at least one of which is from an EU Member State and the others from Member States or Associated Countries; research organisations, companies of any size, public authorities, foundations and associations can participate. Organisations from the United States can also receive EU funding.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition); Specific conditions, Eligibility conditions
What for
A research and innovation action for personalised approaches that reduce the risk of adverse reactions caused by the use of multiple medicines, in order to reduce avoidable hospital admissions and deaths caused by adverse reactions.
Expected Outcome; Scope
What you get
A grant covering 100% of eligible costs; the Commission considers an EU contribution of €8 to 10 million per project appropriate. The indicative budget for the topic is €38 million, expected to fund 4 projects.
Specific conditions (Expected EU contribution per project, Indicative budget); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal between 29 October 2026 and 17 February 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B and, if the proposal includes clinical studies, the annex on clinical studies. Independent experts evaluate and rank the proposals; results are expected approximately 5 months after the deadline.
Planned opening; Deadline(s); Application and evaluation forms; General Annex F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

Reduce avoidable hospital admissions and deaths caused by adverse drug reactions.

01
Fewer adverse reactions for patients
Patients experience fewer adverse reactions from the use of multiple medicines (three or more) and better health outcomes through safer and more effective use of medicines.
02
Prevention of adverse reactions in healthcare
Healthcare professionals can apply strategies to prevent adverse reactions and use genetic and other biomarker information in clinical decisions, especially in cases of comorbidity.
03
Cost savings for healthcare systems
Healthcare systems save costs through fewer hospital admissions and other costs caused by adverse reactions from multiple medicine use.
04
Evidence-based guidelines
Clinical and regulatory guidelines and policies for medication management in multiple medicine use can be revised on the basis of robust evidence.
05
Better information and training
Training programmes for healthcare providers and patients contribute to greater awareness and better management of polypharmacy and adverse reactions.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. Overall, ADRs increase morbidity, mortality, hospitalisations, and healthcare costs.

Read more

ADRs from multiple medications contribute significantly to healthcare costs due to increased hospitalisations and treatments, making this an area of focus to achieve cost efficiency.

Initial failure to recognise ADRs can generate inappropriate prescription cascades, in which the side effects of drugs are misdiagnosed as symptoms of new problems, resulting in further prescriptions and further side effects that tend to accumulate, confusing and complicating the diagnostic while aggravating the evolution.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries:
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
04
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
05
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
06
Subject to restrictions for the protection of European communication networks.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €8 million to €10 million per project appropriate.
€38m · Indicative topic budget, expected to fund 4 projects.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared to two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

17
FEB
HORIZON-HLTH-2027-01-CARE-02 closes 17 February 2027
Open since 29 October 2026
Planned opening; Deadline(s)Active
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative data of the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 40 pages)
  • Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Actual costs in accordance with the Horizon Europe model grant agreement; funding rate 100% (General Annex G).
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Indirect costs as a flat-rate percentage of direct costs in accordance with the model grant agreement.
Travel costs
Other costs
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 6

Subtitle
Subtitle: ChangedShow
Before

Gepersonaliseerde aanpak van bijwerkingen door het gebruik van meerdere geneesmiddelen.

Now

A personalised approach to adverse reactions caused by the use of multiple medicines.

Description
Description: ChangedShow
Before

Projecten ontwikkelen en testen gepersonaliseerde benaderingen om het risico op ernstige bijwerkingen door het gelijktijdig gebruik van meerdere geneesmiddelen te verkleinen, onder meer bij oudere patiënten, zodat zorgverleners en patiënten veiliger kunnen voorschrijven en gebruiken.

Now

Projects develop and test personalised approaches to reduce the risk of serious adverse reactions caused by the concurrent use of multiple medicines, including in older patients, so that healthcare providers and patients can prescribe and use medicines more safely.

Short description
Short description: ChangedShow
Before

Horizon Europe-onderzoeks- en innovatieactie (circa € 8-10 mln per project) voor gepersonaliseerde benaderingen die het risico op bijwerkingen door polyfarmacie verkleinen, met name bij ouderen.

Now

Horizon Europe research and innovation action (approximately €8-10 million per project) for personalised approaches that reduce the risk of adverse drug reactions due to polypharmacy, particularly in older people.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 4 projecten.

Now

Indicative topic budget, expected to fund 4 projects.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 8 mln tot € 10 mln EU-bijdrage per project passend.

Now

No binding maximum; the Commission considers an EU contribution of €8 million to €10 million per project appropriate.

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared to two different EU actions (General Annex G).

Search engine title
Bijwerkingen bij polyfarmacie verminderen (Horizon) becomes Reducing adverse drug reactions in polypharmacy (Horizon)
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe-onderzoeksactie (circa € 8-10 mln) voor gepersonaliseerde aanpak van bijwerkingen door gebruik van meerdere geneesmiddelen.

Now

Horizon Europe research action (approximately €8-10 million) for a personalised approach to adverse reactions from the use of multiple medicines.

Keywords
bijwerkingen van geneesmiddelen, Cluster 1 Health, gepersonaliseerde geneeskunde, Horizon Europe, HORIZON-HLTH-2027-01-CARE-02, polyfarmacie becomes adverse drug reactions, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-01-CARE-02, personalised medicine, polypharmacy
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat becomes Application form Part A: administrative data of the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 40 pages); Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Overheads: Indirecte kosten als forfaitair percentage van de directe kosten volgens de modelsubsidieovereenkomst.

Personnel costs: Werkelijke kosten volgens de modelsubsidieovereenkomst van Horizon Europe; financieringspercentage 100% (General Annex G).

Now

Overheads: Indirect costs as a flat-rate percentage of direct costs in accordance with the model grant agreement.

Personnel costs: Actual costs in accordance with the Horizon Europe model grant agreement; funding rate 100% (General Annex G).

Why this scheme
Why this scheme: ChangedShow
Before

Vermijdbare ziekenhuisopnames en sterfte door bijwerkingen van geneesmiddelen verminderen.

Now

Reduce avoidable hospital admissions and deaths caused by adverse drug reactions.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; onderzoeksinstellingen, bedrijven van elke omvang, overheden, stichtingen en verenigingen kunnen deelnemen. Ook organisaties uit de Verenigde Staten kunnen EU-financiering krijgen.

What for: Een onderzoeks- en innovatieactie voor gepersonaliseerde benaderingen die het risico op bijwerkingen door het gebruik van meerdere geneesmiddelen verkleinen, om vermijdbare ziekenhuisopnames en sterfte door bijwerkingen te verminderen.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 8 tot 10 miljoen per project passend. Het indicatieve budget voor het topic is € 38 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 29 oktober 2026 tot uiterlijk 17 februari 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en deel B en, als het voorstel klinische studies omvat, de bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different countries, at least one of which is from an EU Member State and the others from Member States or Associated Countries; research organisations, companies of any size, public authorities, foundations and associations can participate. Organisations from the United States can also receive EU funding.

What for: A research and innovation action for personalised approaches that reduce the risk of adverse reactions caused by the use of multiple medicines, in order to reduce avoidable hospital admissions and deaths caused by adverse reactions.

What you get: A grant covering 100% of eligible costs; the Commission considers an EU contribution of €8 to 10 million per project appropriate. The indicative budget for the topic is €38 million, expected to fund 4 projects.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal between 29 October 2026 and 17 February 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B and, if the proposal includes clinical studies, the annex on clinical studies. Independent experts evaluate and rank the proposals; results are expected approximately 5 months after the deadline.

Goals
Goals: 5 removed, 5 newShow
Removed

Minder bijwerkingen voor patiënten Patiënten krijgen minder bijwerkingen door het gebruik van meerdere geneesmiddelen (drie of meer) en betere gezondheidsuitkomsten door veiliger en effectiever medicijngebruik.

Preventie van bijwerkingen in de zorg Zorgprofessionals kunnen strategieën toepassen om bijwerkingen te voorkomen en genetische en andere biomarkerinformatie in klinische beslissingen te gebruiken, vooral bij comorbiditeit.

Kostenbesparing voor zorgstelsels Zorgstelsels besparen kosten doordat er minder ziekenhuisopnamen en andere kosten zijn door bijwerkingen van meervoudig medicijngebruik.

Onderbouwde richtlijnen Klinische en regelgevende richtlijnen en beleid voor medicatiebeheer bij meervoudig medicijngebruik kunnen met robuust bewijs worden herzien.

Betere voorlichting en opleiding Opleidingsprogramma's voor zorgverleners en patiënten dragen bij aan meer bewustzijn en beter beheer van polyfarmacie en bijwerkingen.

New

Fewer adverse reactions for patients Patients experience fewer adverse reactions from the use of multiple medicines (three or more) and better health outcomes through safer and more effective use of medicines.

Prevention of adverse reactions in healthcare Healthcare professionals can apply strategies to prevent adverse reactions and use genetic and other biomarker information in clinical decisions, especially in cases of comorbidity.

Cost savings for healthcare systems Healthcare systems save costs through fewer hospital admissions and other costs caused by adverse reactions from multiple medicine use.

Evidence-based guidelines Clinical and regulatory guidelines and policies for medication management in multiple medicine use can be revised on the basis of robust evidence.

Better information and training Training programmes for healthcare providers and patients contribute to greater awareness and better management of polypharmacy and adverse reactions.

Show 5 earlier versions

29 October 2026scheme · version 5

De call is op 29 oktober 2026 geopend. Voorstellen kunnen tot en met 17 februari 2027 worden ingediend.

Status
Opening soon becomes Open

19 October 2026scheme · version 4

Conditions
Conditions: 2 removed, 6 newShow
Removed

Consortium van minimaal 3 partijen Drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minimaal één uit een lidstaat (General Annex B).

Ook Amerikaanse deelnemers financierbaar Juridische entiteiten uit de Verenigde Staten kunnen EU-financiering ontvangen (uitzondering op General Annex B).

New

To be eligible for funding, applicants must be established in one of the following countries:

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

Subject to restrictions for the protection of European communication networks.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; onderzoeksinstellingen, bedrijven van elke omvang, overheden, stichtingen en verenigingen kunnen deelnemen. Ook organisaties uit de Verenigde Staten kunnen EU-financiering krijgen.

What for: Een onderzoeks- en innovatieactie voor gepersonaliseerde benaderingen die het risico op bijwerkingen door het gebruik van meerdere geneesmiddelen verkleinen, om vermijdbare ziekenhuisopnames en sterfte door bijwerkingen te verminderen.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 8 tot 10 miljoen per project passend. Het indicatieve budget voor het topic is € 38 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 29 oktober 2026 tot uiterlijk 17 februari 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en deel B en, als het voorstel klinische studies omvat, de bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. Overall, ADRs increase morbidity, mortality, hospitalisations, and healthcare costs. ADRs from multiple medications contribute significantly to healthcare costs due to increased hospitalisations and treatments, making this an area of focus to achieve cost efficiency. Initial failure to recognise ADRs can generate inappropriate prescription cascades, in which the side effects of drugs are misdiagnosed as symptoms of new problems, resulting in further prescriptions and further side effects that tend to accumulate, confusing and complicating the diagnostic while aggravating the evolution.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: bijwerkingen van geneesmiddelen, Cluster 1 Health, gepersonaliseerde geneeskunde, Horizon Europe, HORIZON-HLTH-2027-01-CARE-02, polyfarmacie
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat
Goals
Goals: 5 newShow
New

Minder bijwerkingen voor patiënten Patiënten krijgen minder bijwerkingen door het gebruik van meerdere geneesmiddelen (drie of meer) en betere gezondheidsuitkomsten door veiliger en effectiever medicijngebruik.

Preventie van bijwerkingen in de zorg Zorgprofessionals kunnen strategieën toepassen om bijwerkingen te voorkomen en genetische en andere biomarkerinformatie in klinische beslissingen te gebruiken, vooral bij comorbiditeit.

Kostenbesparing voor zorgstelsels Zorgstelsels besparen kosten doordat er minder ziekenhuisopnamen en andere kosten zijn door bijwerkingen van meervoudig medicijngebruik.

Onderbouwde richtlijnen Klinische en regelgevende richtlijnen en beleid voor medicatiebeheer bij meervoudig medicijngebruik kunnen met robuust bewijs worden herzien.

Betere voorlichting en opleiding Opleidingsprogramma's voor zorgverleners en patiënten dragen bij aan meer bewustzijn en beter beheer van polyfarmacie en bijwerkingen.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
16 November 2026 by the Twin editors
Start your application

Start your HORIZON-HLTH-2027-01-CARE-02 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.